Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality o… (NCT07255001) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life
Canada50 participantsStarted 2025-12
Plain-language summary
The goal of this clinical trial is to measure hand grip strength in adults with pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are:
* Is it feasible to measure hand grip strength as part of a clinic visit?
* Are changes in hand grip strength related to changes in body composition?
* Is hand grip strength related to a person's well-being?
* Is hand grip strength related to how a tumour responds to treatment?
Participants will squeeze a device with their hand to measure their hand grip strength and complete questionnaires about their well-being when they are seen in clinic for their regular medical care for PDAC.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 18 years or older.
* Histological and/or radiological diagnosis of resectable, non-resectable, or metastatic PDAC. For resectable PDAC, adjuvant setting only.
* ECOG performance status 0-2.
* Life expectancy greater than 6 months as judged by the investigator.
* Planned for treatment, either as part of routine care or in combination with an investigational agent within another study.
* Ability to hold a dynamometer with one hand.
Exclusion Criteria:
* Individuals with CT imaging performed outside of Vancouver, BC, Canada.
* Individuals who are unfit to undergo CT imaging of the third lumbar vertebra (L3).
* Individuals who are currently participating in a structured moderate intensity resistance training program.
* Individuals who are otherwise judged by the investigator to be unfit to proceed with this protocol.
* Unable to comply with study assessments and follow-up.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Frequency of Participants with Hand Grip Strength (HGS) Measurements at 6 Months From Treatment Start Date
Timeframe: From the date anti-cancer therapy is initiated until the 6-month follow-up assessment.